In the current landscape, Asian markets are navigating a complex environment marked by global trade tensions and economic uncertainties, which have led to fluctuations in major indices. Amidst these challenges, investors are increasingly seeking opportunities in undervalued stocks that may offer potential growth despite broader market volatility. Identifying such stocks requires a keen eye for companies with strong fundamentals and resilience to external pressures.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
T’Way Air (KOSE:A091810) |
₩1829.00 |
₩3616.04 |
49.4% |
|
SpiderPlus (TSE:4192) |
¥505.00 |
¥997.79 |
49.4% |
|
Shenzhen KSTAR Science and Technology (SZSE:002518) |
CN¥23.28 |
CN¥46.26 |
49.7% |
|
Nanya Technology (TWSE:2408) |
NT$44.45 |
NT$87.38 |
49.1% |
|
Nan Ya Printed Circuit Board (TWSE:8046) |
NT$176.00 |
NT$349.85 |
49.7% |
|
Livero (TSE:9245) |
¥1761.00 |
¥3461.62 |
49.1% |
|
Insource (TSE:6200) |
¥933.00 |
¥1843.47 |
49.4% |
|
Forum Engineering (TSE:7088) |
¥1237.00 |
¥2434.83 |
49.2% |
|
Dive (TSE:151A) |
¥956.00 |
¥1885.49 |
49.3% |
|
cottaLTD (TSE:3359) |
¥439.00 |
¥870.08 |
49.5% |
Let’s uncover some gems from our specialized screener.
Overview: Shanghai OPM Biosciences Co., Ltd. offers cell culture media and CDMO services both in China and internationally, with a market cap of CN¥6.93 billion.
Operations: Shanghai OPM Biosciences Co., Ltd. generates revenue through its provision of cell culture media and CDMO services across domestic and international markets.
Estimated Discount To Fair Value: 29.0%
Shanghai OPM Biosciences is trading at CN¥61, significantly undervalued compared to its estimated fair value of CN¥85.97, suggesting a 29% discount. Despite a volatile share price and unsustainable dividends at 0.69%, the company shows promising growth prospects with earnings expected to grow significantly by over 20% annually and revenue projected to increase by 23.8% per year, outpacing the broader Chinese market’s growth rate.
Overview: Future Corporation offers IT consulting and services mainly in Japan, with a market capitalization of ¥209.63 billion.
Operations: The company’s revenue segments include Business Innovation at ¥8.38 billion and IT Consulting & Services, encompassing package software and services as well as IT consulting, at ¥64.23 billion.













